10.1111/j.1365-2982.2012.01891.x Neurogastroenterol
Final thoughts GLP-1 medications offer a powerful solution for individuals with obesity-related health conditions, including sleep apnea
While it has a lower glycemic index than white sugar, it can still raise blood sugar levels, making it a less ideal choice for GLP-1 users seeking optimal blood sugar control
Yes, many clinicians are safely prescribing GLP-1s (like Wegovy and Zepbound ) to people who are already receiving HRT
Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation
While semaglutide can reduce your appetite, you still need to ensure that youre maintaining a caloric deficit
